NOTE: as per the ASX announcement.
summary of key numbers below.
1Q22 REVENUE OF $12.3M, A RECORD QUARTERLY RESULT, UP 99% COMPARED TO PCP
• Clinical Trials revenue of $11.1m, up 93% compared to PCP
• Healthcare revenue of $1.1m, up 255% compared to PCP*
CLINICAL TRIALS SALES CONTRACTS OF $40.8M, A RECORD QUARTERLY RESULT, UP 391% COMPARED TO PCP
TOTAL REVENUE BACKLOG OF $130 MILLION, A RECORD RESULT, UP 202% COMPARED TO PCP
• Clinical Trials revenue backlog of $88.0 million, up 109% compared to PCP
• Healthcare revenue backlog of $42.0 million
NET CASH OF $23.4M AT 30 SEPTEMBER 2021**
• Cash inflow from operations of $0.4m, excluding movements in passthrough costs paid on behalf of
customers
• Net cash increased $1.0m from $22.4m at 30 June 2021, including proceeds from exercise of employee
share options of $0.97m
GUIDANCE IN RESPECT OF FY22 REMAINS UNCHANGED
• Clinical Trials revenue under contract as at 30 September 2021 is $33.9m; Clinical Trials contribution margin
expected to be consistent with FY21; Healthcare revenue under contract of $4.2m and a contribution in the range of $2.5 - $3.0m; and Group EBIT margins in the range of 15-18%.
